Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA- DR molecules

Gang Zeng, Christopher E. Touloukian, Xiang Wang, Nicholas P. Restifo, Steven A. Rosenberg, Rong Fu Wang

Research output: Contribution to journalArticle

Abstract

In previous studies, the shared cancer-testis Ag, NY-ESO-1, was demonstrated to be recognized by both Abs and CD8+ T cells. Gene expression of NY-ESO-1 was detected in many tumor types, including melanoma, breast, and lung cancers, but was not found in normal tissues, with the exception of testis. In this study, we describe the identification of MHC class II- restricted T cell epitopes from NY-ESO-1. Candidate CD4+ T cell peptides were first identified using HLA-DR4 transgenic mice immunized with the NY- ESO-1 protein. NY-ESO-1-specific CD4+ T cells were then generated from PBMC of a patient with melanoma stimulated with the candidate peptides in vitro. These CD4+ T cells recognized NY-ESO-1 peptides or protein pulsed on HLA- DR4+ EBV B cells, and also recognized tumor cells expressing HLA-DR4 and NY- ESO-1. A 10-mer peptide (VLLKEFTVSG) was recognized by CD4+ T cells. These studies provide new opportunities for developing more effective vaccine strategies by using tumor-specific CD4+ T cells. This approach may be applicable to the identification of CD4+ T cell epitopes from many known tumor Ags recognized by CD8+ T cells.

Original languageEnglish (US)
Pages (from-to)1153-1159
Number of pages7
JournalJournal of Immunology
Volume165
Issue number2
StatePublished - Jul 15 2000
Externally publishedYes

Fingerprint

T-Lymphocyte Epitopes
HLA-DR Antigens
T-Lymphocytes
HLA-DR4 Antigen
Peptides
Melanoma
Neoplasms
Testicular Neoplasms
Human Herpesvirus 4
Transgenic Mice
Testis
Lung Neoplasms
Proteins
B-Lymphocytes
Vaccines
Breast Neoplasms
Gene Expression

ASJC Scopus subject areas

  • Immunology

Cite this

Zeng, G., Touloukian, C. E., Wang, X., Restifo, N. P., Rosenberg, S. A., & Wang, R. F. (2000). Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA- DR molecules. Journal of Immunology, 165(2), 1153-1159.

Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA- DR molecules. / Zeng, Gang; Touloukian, Christopher E.; Wang, Xiang; Restifo, Nicholas P.; Rosenberg, Steven A.; Wang, Rong Fu.

In: Journal of Immunology, Vol. 165, No. 2, 15.07.2000, p. 1153-1159.

Research output: Contribution to journalArticle

Zeng, G, Touloukian, CE, Wang, X, Restifo, NP, Rosenberg, SA & Wang, RF 2000, 'Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA- DR molecules', Journal of Immunology, vol. 165, no. 2, pp. 1153-1159.
Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA- DR molecules. Journal of Immunology. 2000 Jul 15;165(2):1153-1159.
Zeng, Gang ; Touloukian, Christopher E. ; Wang, Xiang ; Restifo, Nicholas P. ; Rosenberg, Steven A. ; Wang, Rong Fu. / Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA- DR molecules. In: Journal of Immunology. 2000 ; Vol. 165, No. 2. pp. 1153-1159.
@article{bd8f944306094ae3aceb1a1ffd15d357,
title = "Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA- DR molecules",
abstract = "In previous studies, the shared cancer-testis Ag, NY-ESO-1, was demonstrated to be recognized by both Abs and CD8+ T cells. Gene expression of NY-ESO-1 was detected in many tumor types, including melanoma, breast, and lung cancers, but was not found in normal tissues, with the exception of testis. In this study, we describe the identification of MHC class II- restricted T cell epitopes from NY-ESO-1. Candidate CD4+ T cell peptides were first identified using HLA-DR4 transgenic mice immunized with the NY- ESO-1 protein. NY-ESO-1-specific CD4+ T cells were then generated from PBMC of a patient with melanoma stimulated with the candidate peptides in vitro. These CD4+ T cells recognized NY-ESO-1 peptides or protein pulsed on HLA- DR4+ EBV B cells, and also recognized tumor cells expressing HLA-DR4 and NY- ESO-1. A 10-mer peptide (VLLKEFTVSG) was recognized by CD4+ T cells. These studies provide new opportunities for developing more effective vaccine strategies by using tumor-specific CD4+ T cells. This approach may be applicable to the identification of CD4+ T cell epitopes from many known tumor Ags recognized by CD8+ T cells.",
author = "Gang Zeng and Touloukian, {Christopher E.} and Xiang Wang and Restifo, {Nicholas P.} and Rosenberg, {Steven A.} and Wang, {Rong Fu}",
year = "2000",
month = "7",
day = "15",
language = "English (US)",
volume = "165",
pages = "1153--1159",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA- DR molecules

AU - Zeng, Gang

AU - Touloukian, Christopher E.

AU - Wang, Xiang

AU - Restifo, Nicholas P.

AU - Rosenberg, Steven A.

AU - Wang, Rong Fu

PY - 2000/7/15

Y1 - 2000/7/15

N2 - In previous studies, the shared cancer-testis Ag, NY-ESO-1, was demonstrated to be recognized by both Abs and CD8+ T cells. Gene expression of NY-ESO-1 was detected in many tumor types, including melanoma, breast, and lung cancers, but was not found in normal tissues, with the exception of testis. In this study, we describe the identification of MHC class II- restricted T cell epitopes from NY-ESO-1. Candidate CD4+ T cell peptides were first identified using HLA-DR4 transgenic mice immunized with the NY- ESO-1 protein. NY-ESO-1-specific CD4+ T cells were then generated from PBMC of a patient with melanoma stimulated with the candidate peptides in vitro. These CD4+ T cells recognized NY-ESO-1 peptides or protein pulsed on HLA- DR4+ EBV B cells, and also recognized tumor cells expressing HLA-DR4 and NY- ESO-1. A 10-mer peptide (VLLKEFTVSG) was recognized by CD4+ T cells. These studies provide new opportunities for developing more effective vaccine strategies by using tumor-specific CD4+ T cells. This approach may be applicable to the identification of CD4+ T cell epitopes from many known tumor Ags recognized by CD8+ T cells.

AB - In previous studies, the shared cancer-testis Ag, NY-ESO-1, was demonstrated to be recognized by both Abs and CD8+ T cells. Gene expression of NY-ESO-1 was detected in many tumor types, including melanoma, breast, and lung cancers, but was not found in normal tissues, with the exception of testis. In this study, we describe the identification of MHC class II- restricted T cell epitopes from NY-ESO-1. Candidate CD4+ T cell peptides were first identified using HLA-DR4 transgenic mice immunized with the NY- ESO-1 protein. NY-ESO-1-specific CD4+ T cells were then generated from PBMC of a patient with melanoma stimulated with the candidate peptides in vitro. These CD4+ T cells recognized NY-ESO-1 peptides or protein pulsed on HLA- DR4+ EBV B cells, and also recognized tumor cells expressing HLA-DR4 and NY- ESO-1. A 10-mer peptide (VLLKEFTVSG) was recognized by CD4+ T cells. These studies provide new opportunities for developing more effective vaccine strategies by using tumor-specific CD4+ T cells. This approach may be applicable to the identification of CD4+ T cell epitopes from many known tumor Ags recognized by CD8+ T cells.

UR - http://www.scopus.com/inward/record.url?scp=0034662263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034662263&partnerID=8YFLogxK

M3 - Article

C2 - 10878395

AN - SCOPUS:0034662263

VL - 165

SP - 1153

EP - 1159

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -